Retatrutide is the first triple-agonist medication to complete Phase 2 trials for weight loss
The following symptoms indicate the need for immediate medical care: Abdominal pain that lasts hours and/or is so debilitating you cant move Ongoing vomiting and nausea Fever or chills Jaundice, which is the yellowing of the eyes or skin Light-colored stools Urine is the color of black tea Bottom Line GLP-1 medications carry a real, documented risk of gallstones and gallbladder disease, largely because rapid weight loss and reduced gallbladder motility work together to encourage cholesterol buildup
Switching from semaglutide to tirzepatide or vice versa without proper dose adjustment can lead to suboptimal blood sugar control or increased side effects such as nausea, vomiting, or hypoglycemia
doi: 10.1007/s11695-025-07703-0, Summary Keywords content characteristics, creator identity, information quality, semaglutide, short-video platforms, side effects Citation Song J, He X, Cui Z, Sun Y, Liu Y, Yu H, Li A and Jin M (2026) Quality and reliability of semaglutide content on different Chinese short video platforms: a study focusing on side effects
Although preclinical studies suggest that GLP-1RAs may attenuate Alzheimers disease (AD) progression [44, 45], phase III semaglutide trials (NCT04777396, NCT04777409) did not demonstrate clinical benefit
